SPY304.32+1.35 0.45%
DIA254.29-0.06 -0.02%
IXIC9,489.87+120.88 1.29%

Canaccord Genuity Maintains Buy on Halozyme Therapeutics, Raises Price Target to $27

Canaccord Genuity maintains Halozyme Therapeutics (NASDAQ:HALO) with a Buy and raises the price target from $23 to $27.

Benzinga · 05/19/2020 15:42

Canaccord Genuity maintains Halozyme Therapeutics (NASDAQ:HALO) with a Buy and raises the price target from $23 to $27.